Integra LifeSciences Holdings (IART)
Solvency ratios
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.27 | 0.37 | 0.33 | 0.37 | 0.39 |
| Debt-to-capital ratio | 0.41 | 0.47 | 0.42 | 0.45 | 0.48 |
| Debt-to-equity ratio | 0.70 | 0.88 | 0.72 | 0.82 | 0.93 |
| Financial leverage ratio | 2.61 | 2.38 | 2.16 | 2.25 | 2.39 |
Integra LifeSciences Holdings has shown a decreasing trend in its solvency ratios over the past five years. The Debt-to-assets ratio has decreased from 0.39 in 2020 to 0.27 in 2024, indicating that the company's total debt relative to its total assets has declined, which generally reflects a stronger financial position.
Similarly, the Debt-to-capital ratio has decreased from 0.48 in 2020 to 0.41 in 2024, suggesting that the proportion of the company's capital structure represented by debt has also decreased over this period.
The Debt-to-equity ratio has shown a declining trend from 0.93 in 2020 to 0.70 in 2024, indicating a decreasing reliance on debt financing relative to equity financing.
The Financial leverage ratio has fluctuated between 2.16 and 2.61 over the five-year period, reflecting the company's ability to meet its financial obligations through a mix of debt and equity.
Overall, the declining trend in these solvency ratios indicates that Integra LifeSciences Holdings has been effectively managing its debt levels and strengthening its financial position over the years, which is generally positive for the company's long-term financial stability and sustainability.
Coverage ratios
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Interest coverage | — | 2.58 | 5.31 | 5.26 | 2.31 |
The interest coverage ratio of Integra LifeSciences Holdings has shown fluctuations over the years. In December 31, 2020, the interest coverage ratio was 2.31, indicating that the company's operating income was able to cover its interest expenses 2.31 times.
Subsequently, there was a significant improvement as the interest coverage ratio increased to 5.26 in December 31, 2021, and further slightly increased to 5.31 in December 31, 2022. These higher ratios suggest that the company's ability to cover its interest payments improved, depicting a more favorable financial position.
However, there was a slight decline in the interest coverage ratio to 2.58 in December 31, 2023. This ratio decrease signals that the company's operating income may have been less able to cover its interest expenses compared to the previous years.
The information for December 31, 2024 is not available (indicated as "—"), thereby preventing a current assessment of the interest coverage ratio for that year.
Overall, the trend indicates that Integra LifeSciences Holdings has shown some variability in its ability to cover interest expenses in recent years, with notable improvements in some periods and a slight decline in others. Monitoring this ratio across future periods will be important to assess the company's financial stability and debt repayment capacity.